Navigation Links
Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials
Date:5/4/2010

utive Chairman of ANAVEX. "The highly selective binding properties of ANAVEX 2-73 has led to beneficial effects at very low doses, which may ultimately lead to a favorable tolerability profile and offer a wide therapeutic index. This may mean many patients could benefit from low doses, although going to higher doses may be possible in some patients to offer greater efficacy without compromising on the tolerability profile. ANAVEX is confident in the emerging profile of ANAVEX 2-73 as it prepares for Phase 1 clinical trials. We have established that sigma receptors are druggable targets and we have worked to shape ANAVEX 2-73 as our optimized lead compound, which may prove to be neuroprotective."

When administered prior to amyloid-beta 25-35 peptide, ANAVEX 2-73 protected against the amyloid peptide-induced learning deficits, hippocampal lipid peroxidation and cell loss in the CA1 pyramidal layer and showed potent neuroprotective activity. Extensive in-vitro receptor binding and electrophysiology studies, sigma receptor binding studies and electrophysiological effects on sodium and calcium currents have been completed.

The binding affinities of ANAVEX 2-73 for more than 50 receptors were studied. The potency of ANAVEX 2-73, inhibiting enzyme activities was also studied on enzyme assays including calpain, nitric oxide synthase (constitutive and inducible form), protein kinase (PKCa and PKCss), EGF receptor kinase and calcineurin.

"On average in the industry, it takes six and a half years for discovery and preclinical testing to yield a potentially viable lead compound. Over 80% of compounds fail in preclinical stages, before arriving at this stage of research. ANAVEX 2-73 is a novel oral disease modification agent that is believed to act at several levels, including the mitochondria, and may offer a therapy that could be used as a standalone or in combination with other age
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
2. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
3. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
4. Anavex strengthens Board of Directors
5. Anavex advances drug candidate for treatment of Alzheimers disease
6. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
9. BMP Sunstone Reports Fourth Quarter and Full Year 2009 Financial Results
10. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
11. The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis and Growth Opportunities Now Available on ReportsandReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... study published today in the journal PNAS (Proceedings ... that time of day and sleep deprivation have a ... crucial when looking at the best time of day ... disease, and for administering medicines effectively. , Researchers from ... Research, London, investigated the links between sleep deprivation, body ...
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... (Pink Sheets: BSTC.PK) today announced that it sold,200,000 ... private placement,offering to an investment fund, at a ... to the Company of $2,100,000., About BioSpecifics ... biopharmaceutical company that has,developed and licensed injectable collagenase ...
... is seeking nominations for the Third Annual Greater ... March 18, 2008. Those,interested in nominating a company ... The four award categories are: Entrepreneurial, Best ... Award. Nominators will,be asked to submit documentation and ...
... multiplexing module, SANTA ROSA, Calif., Jan. 14 ... provider of optical components for industrial,applications, is to ... technology. The compact LED combining module, which utilizes,proprietary ... medical instrumentation. The ZoroLight LED module will be,on ...
Cached Biology Technology:Bookham to Enter Biomedical Illumination Market 2Bookham to Enter Biomedical Illumination Market 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... new study has revealed that mother birds can provide ... sired with their non-social partner (known as extra-pair offspring). ... birds commonly mate with males other than their social ... interloper,s ,extra pair, offspring often outperform their half brothers ...
... Technology for the first time have shown the earliest ... formation of bones, teeth and sea shells. ... capture a three-dimensional image of the nanoparticles that form ... greater understanding of the formation of bones, teeth and ...
... in US women of childbearing age, and is common in ... in the vagina is disrupted and replaced by an overgrowth ... increased risk for a variety of complications, such as preterm ... be prevented. Vitamin D may play a role in BV ...
Cached Biology News:Mothers give interloper's offspring a head start in life 2Mothers give interloper's offspring a head start in life 3Focus on the formation of bones, teeth and shells 2Vitamin D insufficiency linked to bacterial vaginosis in pregnant women 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... provide fast and reliable automation for ... drug development laboratories. Staccato Mini-Workstations offer ... automate basic liquid handling and material ... with either Caliper's time proven CLARA™ ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Fermentation System to achieve high ... and maximum information output 4 ... precision with small-scale requirements provides users ... with E.coli, Pichia pastoris, yeast, fungi ...
Biology Products: